QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

$5.00
0.00 (0.00%)
(As of 02:21 PM ET)
Today's Range
$4.97
$5.04
50-Day Range
$4.93
$8.32
52-Week Range
$4.85
$12.43
Volume
681,592 shs
Average Volume
2.40 million shs
Market Capitalization
$723.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Aurinia Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
100.8% Upside
$10.00 Price Target
Short Interest
Healthy
8.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to $0.55 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

716th out of 938 stocks

Pharmaceutical Preparations Industry

328th out of 433 stocks

AUPH stock logo

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

AUPH Stock Price History

AUPH Stock News Headlines

11 Oversold Biotech Stocks To Buy Right Now
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AUPH Mar 2024 3.000 call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Aurinia Pharmaceuticals Inc (AUPH)
AUPH Oct 2024 8.000 call
AUPH Jan 2025 15.000 call
AUPH Oct 2024 6.000 put
Earnings Outlook For Aurinia Pharmaceuticals
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+98.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-78,020,000.00
Pretax Margin
-44.14%

Debt

Sales & Book Value

Annual Sales
$175.51 million
Book Value
$2.63 per share

Miscellaneous

Free Float
138,399,000
Market Cap
$727.44 million
Optionable
Optionable
Beta
1.37
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


AUPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $8.00 to $13.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2024?

Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of the year. Since then, AUPH shares have decreased by 44.6% and is now trading at $4.98.
View the best growth stocks for 2024 here
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 10,650,000 shares, a decrease of 12.0% from the February 29th total of 12,100,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is currently 4.5 days. Approximately 8.3% of the shares of the company are sold short.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its earnings results on Thursday, February, 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company had revenue of $45.10 million for the quarter, compared to analysts' expectations of $45 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 20.10% and a negative net margin of 44.45%. The firm's revenue was up 58.8% on a year-over-year basis. During the same period last year, the company earned ($0.18) EPS.

What ETFs hold Aurinia Pharmaceuticals' stock?

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings?

Aurinia Pharmaceuticals issued an update on its fourth quarter 2023 earnings guidance on Friday, January, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.0 million-$45.0 million, compared to the consensus revenue estimate of $44.2 million.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (6.64%), Goldman Sachs Group Inc. (1.43%), Goldman Sachs Group Inc. (1.42%), Vanguard Group Inc. (1.04%), Vanguard Group Inc. (1.05%) and Northern Trust Corp (0.74%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners